Smooth Muscle Tumor

01/01/2015 - "The panel of antibodies used in this study is a useful complementary analysis in the assessment of problematic uterine smooth muscle tumors. "
01/01/2014 - "In this study, we analyzed a group of myometrial smooth muscle tumors in what it regards their differential diagnosis utilizing a panel of antibodies consisting of α-SMA, Ki-67, p16, p53, PR and bcl-2. "
04/01/2002 - "An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies."
12/01/2009 - "A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors."
05/01/2004 - "Uterine smooth muscle tumors exhibit a lower MVD than normal myometrium, as assessed using anti-FvW or anti-CD34 antibodies. "

04/01/2002 - "Desmin was positive in almost all smooth muscle tumors except those of epithelioid type, which were positive in only about half of the cases. "
08/01/1999 - "Currently, the immunohistochemical evaluation of smooth muscle differentiation is usually based on desmin, which also reacts with skeletal muscle and is not present in all smooth muscle tumors, and alpha-smooth muscle actin, which reacts with myoepithelial cells. "
04/01/1991 - "On the contrary, coexpression of desmin and HHF35 while negative for GFAP, S-100 and Leu-7 are suggestive of smooth muscle tumor. "
05/01/1987 - "Immunohistochemical demonstration of desmin in canine smooth muscle tumors."
10/01/2003 - "The 7 tumors classified as non-GISTs had the following immunohistochemical characteristics: 1 was a CD117-negative CD34-positive stromal tumor (GINST) [1/81, 1.2%]; 3 were schwannomas with strong S-100-positive characteristics (3/81, 3.7%); and 3 were smooth muscle tumors with both SMA- and desmin-positive status (3/81, 3.7%). "

11/01/2003 - "Smooth muscle tumors were positive for vimentin and SMA and negative for cytokeratins. "
04/01/1988 - "Immunohistochemistry of desmin and vimentin in smooth muscle tumors of the digestive tract."
07/01/1987 - "The intermediate filament typing of skeletal and smooth muscle tumors has shown that these neoplasms are characterized by the combined expression of desmin and vimentin intermediate filaments. "
03/01/2006 - "We retrospectively analyzed a total of 129 surgically resected primary tumors or metastases of 72 GISTs, 29 smooth muscle tumors, seven PNSTs and 21 desmoid-type fibromatosis by immunohistochemistry for c-kit, CD34, smooth muscle actin, desmin, vimentin, S-100 and L1 expression. "
01/01/2005 - "Eighty-five cases of gastrointestinal mesenchymal tumors including 74 cases of GIST, 8 esophageal smooth muscle tumor, 1 rectal leiomyosarcoma, 1 Schwannoma, and 1 malignant fibrous histiocytoma were studied by histological evaluation along with an immunohistochemistry panel including vimentin, CD117 (c-kit), CD34, SMA, desmin and S-100. "

01/01/2015 - "We used mitosis specific marker PHH3 to count mitotic indexes (MI) of uterine smooth muscle tumors and compared with the mitotic indexes of hematoxylin and eosin (H&E). "
10/01/2009 - "In this study we performed transcervical needle biopsy on 475 patients, 8 LMS patients and 467 patients with non-sarcomas (non-LMS) in a high-risk group for LMS, and evaluated whether examinations performed with Ki-67 and CD34 immunohistochemical analyses in addition to the standard hematoxylin-eosin (H&E)-stained sections would improve preoperative diagnostic precision of the uterine smooth muscle tumors. "
07/01/2009 - "In this study, we evaluated the MI of 2 subsets of uterine smooth muscle tumors--6 leiomyosarcomas (LMS) and 6 smooth muscle tumors of undetermined malignant potential (STUMP)--using PHH3-labeled sections and hematoxylin and eosin (H&E)-stained slides. "
07/01/2014 - "Hematoxylin and eosin-stained slides of uterine smooth-muscle tumors were prospectively analyzed for features suggesting hereditary leiomyomatosis and renal cell carcinoma syndrome, such as prominent eosinophilic macronucleoli with perinucleolar halos, yielding nine cases. "

01/01/2015 - "We used mitosis specific marker PHH3 to count mitotic indexes (MI) of uterine smooth muscle tumors and compared with the mitotic indexes of hematoxylin and eosin (H&E). "
10/01/2009 - "In this study we performed transcervical needle biopsy on 475 patients, 8 LMS patients and 467 patients with non-sarcomas (non-LMS) in a high-risk group for LMS, and evaluated whether examinations performed with Ki-67 and CD34 immunohistochemical analyses in addition to the standard hematoxylin-eosin (H&E)-stained sections would improve preoperative diagnostic precision of the uterine smooth muscle tumors. "
07/01/2009 - "In this study, we evaluated the MI of 2 subsets of uterine smooth muscle tumors--6 leiomyosarcomas (LMS) and 6 smooth muscle tumors of undetermined malignant potential (STUMP)--using PHH3-labeled sections and hematoxylin and eosin (H&E)-stained slides. "
07/01/2014 - "Hematoxylin and eosin-stained slides of uterine smooth-muscle tumors were prospectively analyzed for features suggesting hereditary leiomyomatosis and renal cell carcinoma syndrome, such as prominent eosinophilic macronucleoli with perinucleolar halos, yielding nine cases. "

12/01/1995 - "[Gastrointestinal smooth muscle tumors: a study of DNA content and the association with clinicopathology]."
01/01/2013 - "Interestingly, the non-random distribution of breakpoints within the deletion hotspot region may point to a role of non-canonical DNA structures for the occurrence of these mutations and the molecular pathogenesis of uterine smooth muscle tumors, respectively."
01/01/2013 - "Molecular topography of the MED12-deleted region in smooth muscle tumors: a possible link between non-B DNA structures and hypermutability."
12/01/1995 - "The results suggested that DNA content and ploidy pattern be used as an objective parameter to distinguish malignants from benigns and predict the prognosis of patients with gastrointestinal smooth muscle tumors."
12/01/1995 - "Quantitative analysis of DNA content and ploidy pattern was performed in 84 cases of smooth muscle tumors of the gastrointestinal tract by flow cytometry, and the results were correlated with histopathologic features. "

01/01/2015 - "The aim of the study was to investigate the diagnostic value of progesterone receptor (PR), p16, p53 and pHH3 expression in a series of uterine smooth muscle tumors. "
01/01/2012 - "Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors."
03/01/2010 - "Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. "
01/01/2005 - "The expression of Ki-67, p53 and progesterone receptors is promising in immunodifferentiation of smooth muscle tumors of the uterus with malignant potential."
04/01/2004 - "Our data indicate that the progesterone receptor may be an especially useful marker to distinguish cases of malignant smooth muscle tumors in which histological features are ambiguous or borderline."

05/01/2011 - "The purpose of this study is to define the frequency and patterns of expression of 3 proteins in this pathway (mTOR, Akt, and PI3-K) in smooth muscle tumors of the uterine corpus, and to establish whether the expression of any of these proteins has independent prognostic significance. "
05/01/2008 - "[The morphofunctional characteristics of proteins of nucleolar organizers in uterine smooth muscle tumors]."
09/01/2003 - "Although the sustained clonal expansion in EBV-related smooth-muscle tumors/IPTs may depend on functions provided by the EBV oncogenic proteins, the tumor phenotype may be further modified by the secondary genomic rearrangements imposed by the virus during and/or after the integration event. "
07/01/2008 - "We had immunohistochemically studied the expression of p16, p53, and Ki-67 proteins in 100 cases of uterine smooth muscle tumors, including 35 usual leiomyomas (LM), 13 cellular leiomyomas (CLM), 15 bizarre leiomyomas (BLM), 2 cases of smooth muscle tumor of uncertain malignant potential (STUMP), and 35 leiomyosarcoma (LMS). "
04/01/2006 - "The significant differential expression of apoptotic and cell cycle regulatory proteins in uterine leiomyosarcoma as compared to benign smooth muscle tumors suggests that pathways involving these proteins may be important in the development of malignant disease and, therefore, could be potential targets for molecular therapies."

04/01/2002 - "4) The absence of h-caldesmon in UTROSCTs helps separate them from epithelioid smooth muscle tumors. "
05/01/2000 - "Its isoform, high-molecular-weight caldesmon (h-CD), was demonstrated to be specific for smooth muscle cells and smooth muscle tumors of the soft tissue and to never be expressed in myofibroblasts. "
05/01/2000 - "h-Caldesmon as a specific marker for smooth muscle tumors. "
09/01/2008 - "The importance of CD10 and h-Caldesmon in the distinction of smooth muscle tumors of the uterus and endometrial stromal sarcoma."
04/01/2002 - "h-caldesmon was positive in almost all nonepithelioid smooth muscle tumors and in areas of smooth muscle differentiation in endometrial stromal tumors; it was positive in only about half of the epithelioid smooth muscle tumors and negative in all UTROSCTs. "

10/01/2006 - "Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study."

04/01/2014 - "Multifocal histologically malignant Epstein-Barr virus-associated smooth muscle tumor in a pediatric transplant patient with an indolent course."
10/01/2013 - "We herein describe 2 new cases of EBV-associated post-transplant smooth muscle tumors (EBV-PTSMT), including the first in a facial composite tissue graft recipient. "
06/01/2013 - "Epstein-Barr virus associated smooth muscle tumors in post transplant pediatric patients two cases of rare locations, and review of the literature."
08/01/2009 - "Epstein-Barr virus-associated smooth muscle tumor of the iris in a patient with transplant: a case report and review of the literature."
03/01/1999 - "We report a case of an EBV-associated smooth-muscle tumor, of unusual location arising in a seven-year-old post-transplant patient who was previously treated for a lymphoproliferative disease. "

06/01/2015 - "We report an Epstein-Barr virus (EBV)-associated pulmonary posttransplant smooth muscle tumor arising in the left lung of a 71-year-old bilateral lung transplant recipient nearly 3 years after transplantation, treated with thoracoscopic wedge resection. "
10/01/2013 - "More recently, the development of rare EBV-associated smooth muscle tumors has been reported in transplant recipients. "
07/01/2013 - "Epstein-Barr virus-associated smooth muscle tumors (EBV SMT) in adult kidney transplant recipients (KTR) are rare. "
12/01/2010 - "Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipient."
09/01/2010 - "Synchronous hepatic, mesenteric and pulmonary Epstein-Barr virus-associated smooth muscle tumors in a renal transplant recipient."

03/01/2015 - "Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review."
10/01/2001 - "Smooth muscle tumors are increasingly recognized in children with various immunodeficiencies occurring after organ transplantation. "
04/01/2000 - "Epstein-Barr virus (EBV)-associated smooth muscle tumors following solid organ transplantation are extremely rare, with only 12 cases reported in the literature thus far. "
09/01/2007 - "Epstein-Barr virus (EBV) associated smooth muscle tumors (SMTs) have been described in patients with acquired immune deficiency syndrome (AIDS) and, more recently, in association with immunosuppression after solid-organ transplantation. "
04/01/2000 - "Our data indicate that EBV infection plays a causal role in the development of smooth muscle tumors following organ transplantation. "

04/01/2000 - "For both benign and malignant smooth muscle tumors of the small intestine, surgery remains the treatment of choice, with little efficacy reported for irradiation, chemotherapy, or both."
03/01/2007 - "EBV-associated smooth muscle tumors may occur in patients who are partially reconstituted after BMT for severe combined immunodeficiency and may not require surgery or chemotherapy."
06/01/2000 - "All tumors, likely metastases of a previous LMS presentation, were classified as small, including eight that developed before chemotherapy; the diagnoses were based on standard immunohistochemistry methods for smooth muscle tumors. "
11/01/1996 - "Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy."

09/01/2001 - "Metachronous Epstein-Barr virus-related smooth muscle tumors in a child after heart transplantation: case report and review of the literature."
04/01/2000 - "We report a 26-year-old man in whom multiple smooth muscle tumors developed 36 to 51 months after heart transplantation. "
11/01/2014 - "These model diseases include plexiform vasculopathy in pulmonary arterial hypertension (PAH), Quilty lesions in heart transplantation, bronchiolitis obliterans (BO), inflammatory airway remodeling and Epstein-Barr virus (EBV) induced smooth muscle proliferation (posttransplantation smooth muscle tumor, PTSMT).Using in situ molecular pathology, we were able to dismiss an assumed involvement of myofibroblastic cells in vessel reconstruction of the lung in PAH. "